Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Assets: 2019-2024

Historic Current Assets for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $249.9 million.

  • Fulcrum Therapeutics' Current Assets fell 23.04% to $205.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $205.9 million, marking a year-over-year decrease of 23.04%. This contributed to the annual value of $249.9 million for FY2024, which is 3.19% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Current Assets of $249.9 million as of FY2024, which was up 3.19% from $242.2 million recorded in FY2023.
  • Fulcrum Therapeutics' Current Assets' 5-year high stood at $249.9 million during FY2024, with a 5-year trough of $119.5 million in FY2020.
  • Its 3-year average for Current Assets is $233.2 million, with a median of $242.2 million in 2023.
  • In the last 5 years, Fulcrum Therapeutics' Current Assets skyrocketed by 89.10% in 2021 and then decreased by 8.18% in 2022.
  • Fulcrum Therapeutics' Current Assets (Yearly) stood at $119.5 million in 2020, then skyrocketed by 89.10% to $226.0 million in 2021, then dropped by 8.18% to $207.5 million in 2022, then climbed by 16.71% to $242.2 million in 2023, then increased by 3.19% to $249.9 million in 2024.